New drug combo targets returned ovarian and uterine cancers
NCT ID NCT05691504
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests the safety and best dose of two drugs, APG-1252 and cobimetinib, given together to people whose ovarian or endometrial cancer has come back. The drugs work by blocking proteins that help cancer cells survive and grow. The goal is to see if the combination can shrink or stabilize tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Experimental drug TJ037130 takes aim at advanced solid tumors
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- Vaccine-Immunotherapy combo takes aim at Hard-to-Treat ovarian cancer
- Engineered immune cells take aim at Hard-to-Treat cancers
- Hormone blocker plus targeted drug shows promise against tough uterine cancer